Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026)
Johnson & Johnson (JNJ) posted Cash from Operations of 2514000000.0 for Q1 2026, down 65.6% sequentially from 7309000000.0 in Q4 2025, and down 39.77% YoY from 4174000000.0 in Q1 2025.
Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Cash from Operations data on file, last reported at 2514000000.0 in Q1 2026.
- Quarterly Cash from Operations fell 39.77% year-over-year to 2514000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 22870000000.0 (down 7.72% YoY) and the FY2025 annual result came in at 24530000000.0, up 1.09% from the prior year.
- Cash from Operations slipped to 2514000000.0 in Q1 2026 per JNJ's latest filing, from 7309000000.0 in the prior quarter.
- The five-year high for Cash from Operations was 9169000000.0 in Q3 2025, with the low at 2514000000.0 in Q1 2026.
- Average Cash from Operations over 5 years is 5439733333.33, with a median of 4182000000.0 recorded in 2023.
- Year-over-year, Cash from Operations surged 123.63% in 2023 and plunged 39.77% in 2026.
- Johnson & Johnson's Cash from Operations stood at 3979000000.0 in 2022, then soared by 97.61% to 7863000000.0 in 2023, then declined by 11.19% to 6983000000.0 in 2024, then gained by 4.67% to 7309000000.0 in 2025, then plunged by 65.6% to 2514000000.0 in 2026.
- Business Quant data shows JNJ's Cash from Operations at 2514000000.0 in Q1 2026, 7309000000.0 in Q4 2025, and 9169000000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.33 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.51 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.83 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 645.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.51 Bn |
| Mar 29, 2026 | 2.51 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Mar 31, 2024 | 3.66 Bn |
| Mar 31, 2024 | 3.66 Bn |
| Dec 31, 2023 | 7.86 Bn |
| Dec 31, 2023 | 7.86 Bn |